본문으로 건너뛰기
← 뒤로

Drug-resistant epicrania fugax: Responding to onabotulinumtoxinA.

Headache 2023 Vol.63(6) p. 839-842 🌐 cited 5 🔓 OA Migraine and Headache Studies
📈 연도별 인용 (2023–2026) · 합계 5
OpenAlex 토픽 · Migraine and Headache Studies Trigeminal Neuralgia and Treatments Ophthalmology and Eye Disorders

Alberola-Amores FJ, Moral-Rubio J

📝 환자 설명용 한 줄

Epicrania fugax (EF) is a primary headache consisting of brief paroxysms of pain, lasting 1-10 s, that move through different nerve territories of one hemicranium with a linear or zigzag trajectory, a

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Francisco José Alberola‐Amores, Jorge Moral‐Rubio (2023). Drug-resistant epicrania fugax: Responding to onabotulinumtoxinA.. Headache, 63(6), 839-842. https://doi.org/10.1111/head.14532
MLA Francisco José Alberola‐Amores, et al.. "Drug-resistant epicrania fugax: Responding to onabotulinumtoxinA.." Headache, vol. 63, no. 6, 2023, pp. 839-842.
PMID 37337680
DOI 10.1111/head.14532

Abstract

Epicrania fugax (EF) is a primary headache consisting of brief paroxysms of pain, lasting 1-10 s, that move through different nerve territories of one hemicranium with a linear or zigzag trajectory, although there are some clinical variants. Preventive therapy with anti-seizure medication such as gabapentin and lamotrigine are most commonly used in patients presenting with frequent and non-remitting attacks. In some cases, greater occipital nerve blockades are used for short- or long-term relief. Here, we report two patients with a paroxysmal EF-type pain who meet the criteria for EF of the International Classification of Headache Disorders, 3rd edition, with clear triggers and autonomic ocular signs and who failed multiple preventive treatments, but had a sustained response to onabotulinumtoxinA.

MeSH Terms

Humans; Botulinum Toxins, Type A; Headache; Pain; Headache Disorders; Gabapentin